Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Brain Health in Breast Cancer Survivors

Recruiting

Conditions: Cognitive Function
Cognitive Impairment

First Posted Date: 2020-03-05

Last Posted Date: 2025-05-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 120

Registration Number: NCT04297020

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States

Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors

Phase 2

Recruiting

Conditions: Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Early-Stage Breast Carcinoma
Prognostic Stage IIB Breast Cancer AJCC v8

Interventions: Drug: Anhydrous Enol-oxaloacetate
Other: Questionnaire Administration

First Posted Date: 2020-03-02

Last Posted Date: 2024-11-05

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT04290897

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Refractory Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8

Interventions: Biological: Necitumumab
Drug: Osimertinib
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Biological: Trastuzumab

First Posted Date: 2020-02-26

Last Posted Date: 2024-06-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT04285671

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

Early Phase 1

Completed

Conditions: Prostate Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Gallium Ga 68-labeled PSMA-11
Dietary Supplement: Monosodium Glutamate
Procedure: Positron Emission Tomography

First Posted Date: 2020-02-25

Last Posted Date: 2020-12-02

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT04282824

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Phase 1

Withdrawn

Conditions: Acute Graft Versus Host Disease
Gastrointestinal Tract Acute Graft Versus Host Disease
Severe Gastrointestinal Tract Acute Graft Versus Host Disease
Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease

Interventions: Drug: Fecal Microbiota Transplantation Capsule

First Posted Date: 2020-02-21

Last Posted Date: 2023-09-22

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT04280471

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Stage IVA Prostate Cancer AJCC v8

Interventions: Procedure: Computed Tomography
Drug: Gallium Ga 68 Gozetotide
Procedure: Positron Emission Tomography

First Posted Date: 2020-02-21

Last Posted Date: 2022-09-21

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 9

Registration Number: NCT04279561

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients with Recurrent or Refractory Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma
Progressive Disease
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma

Interventions: Biological: Anakinra
Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate

First Posted Date: 2019-12-20

Last Posted Date: 2024-12-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 36

Registration Number: NCT04205838

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

Phase 1

Recruiting

Conditions: Recurrent Glioblastoma

Interventions: Biological: Dendritic Cell Tumor Cell Lysate Vaccine
Other: Placebo Administration
Biological: Pembrolizumab
Drug: Poly ICLC

First Posted Date: 2019-12-17

Last Posted Date: 2024-10-16

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT04201873

Locations: 🇺🇸
Quan, Los Angeles, California, United States

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Phase 1

Terminated

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Progesterone Receptor Negative
Anatomic Stage IB Breast Cancer AJCC v8
Invasive Ductal Carcinoma, Not Otherwise Specified
Prognostic Stage 0 Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Biological: Talimogene Laherparepvec

First Posted Date: 2019-12-04

Last Posted Date: 2023-08-15

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT04185311

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Early Phase 1

Recruiting

Conditions: Gastric Carcinoma
Pancreatic Carcinoma
Uterine Corpus Cancer
Colon Carcinoma
Kidney Carcinoma
Lung Carcinoma
Solid Neoplasm
Head and Neck Carcinoma
Breast Carcinoma
Esophageal Carcinoma

Interventions: Procedure: Computed Tomography
Radiation: Gallium Ga 68 FAPi-46
Radiation: Gallium Ga 68-labeled PSMA-11
Procedure: Positron Emission Tomography
Radiation: 18F-FDG

First Posted Date: 2019-11-01

Last Posted Date: 2025-05-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT04147494

Locations: 🇺🇸
Ethan Lam, Los Angeles, California, United States

Home Terms & Conditions Privacy Policy